Trial Profile
Phase I/IIa Study to Assess the Safety, Immunogenicity and Efficacy of AllerT, a Combination of Peptides Derived From Bet v 1, Administered Via the Subcutaneous or Intradermal Route to Volunteers Allergic to Birch Pollen
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Birch pollen allergy immunotherapy-Anergis (Primary) ; Birch pollen allergy immunotherapy-Anergis (Primary)
- Indications Allergic rhinoconjunctivitis; Tree pollen hypersensitivity
- Focus Adverse reactions
- 22 Dec 2012 New trial record
- 08 Nov 2012 Results published in an Anergis media release.